Both beneficial and adverse effects are due to the same mechanism of action, which is inhibition of COX-dependent prostanoids. Since CV and GI risk are related to drug exposure, a reduction in the ...

Table 1. Suggested strategies for analgesic/anti-inflammatory treatment and cardiovascular prevention among patients with inflammatory disease and different levels of risk of vascular events ...

Sotatercept, approved in 2024 in the United States and Europe, was shown in clinical trials to lead to improvements in 6-minute walk distance, hemodynamics, right ventricular function, and ...